Corneal collagen cross-linking in the treatment of progressive keratoconus-preliminary results

To evaluate the efficacy and safety of riboflavin-ultraviolet-A (UV-A)-induced corneal collagen cross-linking (CXL) in the management of progressive keratoconus. It was a retrospective case series study. Twenty-three eyes of 13 patients with progressive keratoconus were included. Corneal collagen cr...

Full description

Saved in:
Bibliographic Details
Published inChung-hua yen k'o tsa chih Vol. 49; no. 10; p. 896
Main Authors Li, Gang, Fan, Zheng-Jun, Peng, Xiu-Jun
Format Journal Article
LanguageChinese
Published China 01.10.2013
Subjects
Adolescent
Adult
Collagen - therapeutic use
Cross-Linking Reagents - therapeutic use
Female
Humans
Keratoconus - drug therapy
Male
Photochemotherapy
Retrospective Studies
Treatment Outcome
Young Adult
Online AccessGet more information

Cover

More Information
Summary:To evaluate the efficacy and safety of riboflavin-ultraviolet-A (UV-A)-induced corneal collagen cross-linking (CXL) in the management of progressive keratoconus. It was a retrospective case series study. Twenty-three eyes of 13 patients with progressive keratoconus were included. Corneal collagen crosslinking was performed under topical anesthesia including corneal de-epithelization (8 mm diameter) and instillation of 0.1% riboflavin (in 20% dextran T500 solution) every 3 minutes for a total of 30 minutes. The irradiation is performed for another 30 min using a solid-state UV-A illuminator at 370 nm and an irradiance of 3 mW/cm(2). Average follow-up was 15.23 ± 3.39 months (range: 12 to 22 months). Visual acuity, corneal topography, in vivo confocal microscopy, and endothelial cell count were evaluated at baseline and at 1, 3, 6, and 12 months follow-up. Mean uncorrected visual acuity(UCVA) and best spectacle-corrected visual acuity (BSCVA) increased 0.115 ± 0.158 LogMAR (t = 3.418, P = 0.0026) and 0.114 ± 0.
ISSN:0412-4081
DOI:10.3760/cma.j.issn.0412-4081.2013.10.007